Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Public ClinicalTrials.gov record NCT05861453. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease
Study identification
- NCT ID
- NCT05861453
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Afimmune
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Epeleuton Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2024
- Primary completion
- Jan 20, 2026
- Completion
- Feb 10, 2026
- Last update posted
- May 3, 2026
2024 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) | Birmingham | Alabama | 35294 | — |
| New England Sickle Cell Institute, UConn Health | Farmington | Connecticut | 06030-1163 | — |
| Medstar Health | Washington D.C. | District of Columbia | 20010 | — |
| Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta at Hughes Spalding | Atlanta | Georgia | 30303 | — |
| Emory University - Georgia Comprehensive Sickle Cell Center | Atlanta | Georgia | 30303 | — |
| Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Atlanta | Georgia | 30329 | — |
| UI Health Sickle Cell Center | Chicago | Illinois | 60612 | — |
| The Johns Hopkins University School of Medicine | Baltimore | Maryland | 21205 | — |
| The Center for Cancer and Blood Disorders, A Division of American Oncology Partners, PA | Bethesda | Maryland | 20817 | — |
| Kaiser Permanente Mid-Atlantic States | Largo | Maryland | 20774 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Robert Wood Johnson Medical School Rutgers | New Brunswick | New Jersey | 08901 | — |
| Newark Beth Israel Medical Center | Newark | New Jersey | 07112 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| UNC Health | Chapel Hill | North Carolina | 27517 | — |
| Science 37 | Morrisville | North Carolina | 27560 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05861453, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05861453 live on ClinicalTrials.gov.